A closely watched coronavirus vaccine invented by the German company CureVac was just 47% effective in a large trial at its interim analysis, a disappointing result that may highlight the challenge posed by virus variants.

A coronavirus vaccine under development from CureVac NV showed a good immune response in early trials, validating the biotech company's 20 years of research into messenger RNA's ability to train the body's defenses.